title: 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010.
abstract: Abstract: Current classification criteria for definite APS recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies (aCL), lupus anticoagulant (LA), and antibodies directed to β(2)glycoprotein I (anti-β(2)GPI) to detect antiphospholipid antibodies (aPL) in the presence of at least one of the two major clinical manifestations (i.e., thrombosis or pregnancy morbidity) of the syndrome. Several other autoantibodies shown to be directed to phospholipids and/or their complexes with phospholipids and/or to proteins of the coagulation cascade, as well as a mechanistic test for resistance to annexin A5 anticoagulant activity, have been proposed to be relevant to APS. A task force of worldwide scientists in the field discussed and analyzed critical questions related to 'non-criteria' aPL tests in an evidence-based manner during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, 13-16 April 2010, Galveston, Texas, USA). This report summarizes the findings, conclusions, and recommendations of this task force.
authors.affiliation: Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, London, UK. maria.bertolaccini@kcl.ac.uk
authors.forename: M L
authors.initials: ML
authors.lastname: Bertolaccini
authors.forename: O
authors.initials: O
authors.lastname: Amengual
authors.forename: T
authors.initials: T
authors.lastname: Atsumi
authors.forename: W L
authors.initials: WL
authors.lastname: Binder
authors.forename: B
authors.initials: B
authors.lastname: de Laat
authors.forename: R
authors.initials: R
authors.lastname: Forastiero
authors.forename: W H
authors.initials: WH
authors.lastname: Kutteh
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: H
authors.initials: H
authors.lastname: Matsubayashi
authors.forename: V
authors.initials: V
authors.lastname: Murthy
authors.forename: M
authors.initials: M
authors.lastname: Petri
authors.forename: J H
authors.initials: JH
authors.lastname: Rand
authors.forename: M
authors.initials: M
authors.lastname: Sanmarco
authors.forename: A E
authors.initials: AE
authors.lastname: Tebo
authors.forename: S S
authors.initials: SS
authors.lastname: Pierangeli
mesh_terms: D026683:Advisory Committees; D017152:Antibodies, Antiphospholipid / Q000032:analysis* / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000175:diagnosis* / Q000276:immunology; D003226:Congresses as Topic; D003955:Diagnostic Tests, Routine / Q000379:methods / Q000592:standards; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D011247:Pregnancy; D011516:Prothrombin / Q000276:immunology; D013781:Texas
chemical_list: D017152:Antibodies, Antiphospholipid; D011516:Prothrombin